Catheter Related Bloodstream Infection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Source of Infection, By Distribution Channel, By Region & Competition, 2021-2031F

Description

The Global Catheter Related Bloodstream Infection Market is projected to expand from USD 1.62 Billion in 2025 to USD 2.25 Billion by 2031, reflecting a compound annual growth rate of 5.63%. This market encompasses a range of infection prevention and treatment solutions, including antimicrobial catheters, antibiotic locks, and site securement devices, all designed to mitigate pathogen risks associated with vascular access. The primary forces driving this growth include the increasing prevalence of chronic diseases necessitating prolonged hospitalization and a growing geriatric population vulnerable to hospital-acquired conditions. Additionally, strict regulatory mandates that penalize healthcare facilities for preventable infection rates are compelling the adoption of specialized sterilization and catheter technologies.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 1.62 Billion
Market Size 2031	USD 2.25 Billion
CAGR 2026-2031	5.63%
Fastest Growing Segment	Retail Pharmacies
Largest Market	North America

However, the market encounters significant obstacles due to the high cost of premium antimicrobial catheters compared to standard options, which restricts their adoption in budget-constrained healthcare settings. This barrier is exacerbated by rigorous reimbursement policies that hold medical facilities financially responsible for treating hospital-acquired infections. Underscoring the continued clinical necessity for effective solutions, the International Nosocomial Infection Control Consortium reported in 2024 that the pooled mean central line-associated bloodstream infection rate among pediatric intensive care patients was 5.37 episodes per 1,000 catheter days.

Market Driver

The introduction of novel catheter lock solutions and therapies is critically influencing the market by offering advanced alternatives to traditional saline or heparin flushes, specifically addressing the clinical need to salvage infected devices rather than removing them. These innovative therapies are gaining traction as healthcare providers seek to reduce the morbidity and logistical complexity associated with central venous catheter replacement. The efficacy of these next-generation solutions is reshaping treatment protocols; according to Citius Pharmaceuticals in May 2024, the Phase 3 Trial of Mino-Lok Antibiotic Lock Solution demonstrated an overall treatment success rate of 57.1% in patients with catheter-related bloodstream infections compared to 37.7% in the control arm, validating the shift toward high-value pharmacological interventions.

The implementation of stringent infection control mandates serves as a primary regulatory force, pushing hospitals to invest in comprehensive prevention bundles and surveillance technologies to avoid financial penalties. Regulatory bodies are increasingly linking reimbursement to safety performance, driving the adoption of standardized catheter care protocols and advanced securement devices. While recent national data from The Leapfrog Group in November 2024 indicates that average central line-associated bloodstream infection scores decreased by 38% since the fall of 2022, compliance brings cost pressures; for instance, CorMedix Inc. established a wholesale acquisition cost of $249.99 per vial for its newly approved antimicrobial catheter lock solution in 2024, illustrating the significant financial investment required to integrate these safeguards.

Market Challenge

The Global Catheter Related Bloodstream Infection Market faces a distinct obstacle regarding the prohibitive cost of premium antimicrobial catheters compared to standard vascular access devices. While these advanced solutions offer enhanced pathogen protection, their elevated price creates a significant barrier for healthcare facilities managing restricted budgets, a friction intensified by reimbursement structures that impose strict penalties for hospital-acquired conditions but often fail to provide adequate funding for upfront preventative technologies. Consequently, cost-sensitive procurement departments frequently opt for standard catheters, substituting expensive device-based solutions with rigorous, labor-intensive sterility protocols to meet regulatory safety standards.

This purchasing behavior directly restricts market revenue growth by limiting the adoption volume of high-margin antimicrobial products. Medical facilities may bypass expensive innovations if they can achieve required safety outcomes through process improvements and standard bundle compliance alone. Highlighting the effectiveness of these alternative containment strategies, The Leapfrog Group noted in 2024 that central line-associated bloodstream infections decreased by 38% over the last two years across surveyed hospitals, suggesting that facilities are effectively controlling infection rates through current measures, potentially diminishing the perceived commercial necessity for investing in higher-cost catheter technologies.

Market Trends

The expansion of infection prevention solutions into home healthcare settings is reshaping market dynamics as care delivery shifts from acute hospital environments to ambulatory and domiciliary models. This transition is driven by the clinical necessity to reduce long-term hospitalization costs and minimize nosocomial exposure, fostering high demand for vascular access devices and sterility products optimized for non-clinical users. Consequently, infusion service providers are witnessing substantial growth; according to Option Care Health in October 2025, the company reported net revenue of $1.435 billion in its third-quarter earnings call, representing a 12.2% increase over the prior year due to the accelerated migration of infusion therapies to the home setting.

Simultaneously, the utilization of AI-driven digital surveillance and data analytics is emerging as a transformative force, enabling healthcare facilities to automate the complex detection of catheter-related pathogens. By integrating machine learning algorithms with electronic health records, institutions can rapidly identify infection clusters and streamline reporting compliance, significantly reducing the administrative burden on infection preventionists. This technological integration enhances diagnostic accuracy and cuts review time; according to Oxford Academic in November 2025, AI-assisted surveillance review required a median of 14 minutes per case compared to 25 minutes for expert review, demonstrating significant efficiency gains through algorithmic monitoring.

Key Market Players

Teva Pharmaceutical Industries Ltd.
SteriMax Inc.
Sanofi S.A.
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
GSK plc
Fresenius SE & Co. KGaA
Eli Lilly and Company
Aurobindo Pharma Limited

Report Scope

In this report, the Global Catheter Related Bloodstream Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Catheter Related Bloodstream Infection Market, By Treatment Type

Anti-microbial Agents
Antibiotic Lock Therapy

Catheter Related Bloodstream Infection Market, By Source of Infection

Coagulase-negative Staphylococcus
S. Aureus
Enteric Gram-negative Bacilli
Yeasts
Enterococci & Streptococci
Pseudomonas
Others

Catheter Related Bloodstream Infection Market, By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Catheter Related Bloodstream Infection Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Catheter Related Bloodstream Infection Market.

Available Customizations:

Global Catheter Related Bloodstream Infection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Catheter Related Bloodstream Infection Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Treatment Type (Anti-microbial Agents, Antibiotic Lock Therapy)
- 5.2.2. By Source of Infection (Coagulase-negative Staphylococcus, S. Aureus, Enteric Gram-negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, Others)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Catheter Related Bloodstream Infection Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Treatment Type
- 6.2.2. By Source of Infection
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Catheter Related Bloodstream Infection Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Treatment Type
    - 6.3.1.2.2. By Source of Infection
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Catheter Related Bloodstream Infection Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Treatment Type
    - 6.3.2.2.2. By Source of Infection
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Catheter Related Bloodstream Infection Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Treatment Type
    - 6.3.3.2.2. By Source of Infection
    - 6.3.3.2.3. By Distribution Channel

7. Europe Catheter Related Bloodstream Infection Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Treatment Type
- 7.2.2. By Source of Infection
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Catheter Related Bloodstream Infection Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Treatment Type
    - 7.3.1.2.2. By Source of Infection
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. France Catheter Related Bloodstream Infection Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Treatment Type
    - 7.3.2.2.2. By Source of Infection
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. United Kingdom Catheter Related Bloodstream Infection Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Treatment Type
    - 7.3.3.2.2. By Source of Infection
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. Italy Catheter Related Bloodstream Infection Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Treatment Type
    - 7.3.4.2.2. By Source of Infection
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Catheter Related Bloodstream Infection Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Treatment Type
    - 7.3.5.2.2. By Source of Infection
    - 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Catheter Related Bloodstream Infection Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Treatment Type
- 8.2.2. By Source of Infection
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Catheter Related Bloodstream Infection Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Treatment Type
    - 8.3.1.2.2. By Source of Infection
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Catheter Related Bloodstream Infection Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Treatment Type
    - 8.3.2.2.2. By Source of Infection
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Catheter Related Bloodstream Infection Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Treatment Type
    - 8.3.3.2.2. By Source of Infection
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Catheter Related Bloodstream Infection Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Treatment Type
    - 8.3.4.2.2. By Source of Infection
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Catheter Related Bloodstream Infection Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Treatment Type
    - 8.3.5.2.2. By Source of Infection
    - 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Catheter Related Bloodstream Infection Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Treatment Type
- 9.2.2. By Source of Infection
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Catheter Related Bloodstream Infection Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Treatment Type
    - 9.3.1.2.2. By Source of Infection
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. UAE Catheter Related Bloodstream Infection Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Treatment Type
    - 9.3.2.2.2. By Source of Infection
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. South Africa Catheter Related Bloodstream Infection Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Treatment Type
    - 9.3.3.2.2. By Source of Infection
    - 9.3.3.2.3. By Distribution Channel

10. South America Catheter Related Bloodstream Infection Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Treatment Type
- 10.2.2. By Source of Infection
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Catheter Related Bloodstream Infection Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Treatment Type
    - 10.3.1.2.2. By Source of Infection
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Colombia Catheter Related Bloodstream Infection Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Treatment Type
    - 10.3.2.2.2. By Source of Infection
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. Argentina Catheter Related Bloodstream Infection Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Treatment Type
    - 10.3.3.2.2. By Source of Infection
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Catheter Related Bloodstream Infection Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Teva Pharmaceutical Industries Ltd.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. SteriMax Inc.
15.3. Sanofi S.A.
15.4. Pfizer Inc.
15.5. Novartis AG
15.6. Merck & Co., Inc.
15.7. GSK plc
15.8. Fresenius SE & Co. KGaA
15.9. Eli Lilly and Company
15.10. Aurobindo Pharma Limited